Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Published:2011-02 Issue:9767 Volume:377 Page:721-731
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Navarra Sandra V,Guzmán Renato M,Gallacher Alberto E,Hall Stephen,Levy Roger A,Jimenez Renato E,Li Edmund K-M,Thomas Mathew,Kim Ho-Youn,León Manuel G,Tanasescu Coman,Nasonov Eugeny,Lan Joung-Liang,Pineda Lilia,Zhong Z John,Freimuth William,Petri Michelle A

Publisher

Elsevier BV

Subject

General Medicine

Reference38 articles.

1. Systemic lupus erythematosus;Rahman;N Engl J Med,2008

2. Mortality in systemic lupus erythematosus;Bernatsky;Arthritis Rheum,2006

3. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients;Cervera;Medicine,2003

4. Infections as triggers and complications of systemic lupus erythematosus;Doria;Autoimmun Rev,2008

5. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease;Campbell;Arthritis Rheum,2008

Cited by 1632 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic glucocorticoid therapy for SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. B cells and generation of antibodies;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Future directions;Dubois' Lupus Erythematosus and Related Syndromes;2025

4. Management of lupus nephritis;Dubois' Lupus Erythematosus and Related Syndromes;2025

5. Targeted therapies in SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025